Mesoblast Ltd's stock plummeted 8.93% during Monday's intraday trading session following a downward revision of its price target by investment firm Jefferies.
The stock decline came after Jefferies reduced its price target for Mesoblast to AU$3.20 per share from AU$3.50 per share, while maintaining a buy rating on the stock. The price target adjustment was part of a broader review of Australian healthcare stocks by the firm.